About Celator Pharmaceuticals
Celator Pharmaceuticals, Inc. is an oncology-focused biopharmaceutical company. The Company is engaged in developing products to improve patient outcomes in cancer. The Company's technology platform, CombiPlex, enables the design and evaluation of optimized combinations incorporating traditional chemotherapies, as well as molecularly targeted agents to deliver anti-cancer activity. The Company's product, VYXEOS, a nano-scale liposomal formulation of cytarabine:daunorubicin, in Phase III clinical testing for the treatment of acute myeloid leukemia. The Company also conducted clinical development efforts on CPX-1, a nano-scale liposomal formulation of irinotecan:floxuridine for the treatment of colorectal cancer; and has a preclinical stage product candidate CPX-8, a hydrophobic docetaxel prodrug nanoparticle formulation. The Company operates in the United States and Canada.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drugs - Generic
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: CPXX
Companies Related to Celator Pharmaceuticals:
- Previous Close: $0.00
- 50 Day Moving Average: $28.68
- 200 Day Moving Average: $12.63
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -91.64
- P/E Growth: 0.00
- Market Cap: $N/A
- Beta: 7.09
Earnings History for Celator Pharmaceuticals (NASDAQ:CPXX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/9/2016|| || || || || || || || |
Earnings Estimates for Celator Pharmaceuticals (NASDAQ:CPXX)
Current Year EPS Consensus Estimate: $-0.60 EPS
Next Year EPS Consensus Estimate: $-0.33 EPS
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Celator Pharmaceuticals (NASDAQ:CPXX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Celator Pharmaceuticals (NASDAQ:CPXX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/3/2015||Scott D Morenstein||Director||Buy||5,000||$1.87||$9,350.00|| |
|10/6/2015||Scott Thomas Jackson||CEO||Buy||14,450||$1.74||$25,143.00|| |
|10/5/2015||Fred M Powell||CFO||Buy||13,700||$1.78||$24,386.00|| |
|10/1/2015||Life Sciences Gp Ll Valence II||insider||Buy||12,200||$1.64||$20,008.00|| |
|11/18/2014||Fred M Powell||CFO||Buy||6,000||$2.20||$13,200.00|| |
|11/18/2014||Michael R Dougherty||Director||Buy||20,000||$2.15||$43,000.00|| |
|11/18/2014||Scott Thomas Jackson||CEO||Buy||10,000||$2.20||$22,000.00|| |
|5/15/2014||Fred M Powell||CFO||Buy||2,500||$2.50||$6,250.00|| |
|12/17/2013||Fred M Powell||CFO||Buy||2,500||$3.50||$8,750.00|| |
|12/17/2013||Scott Thomas Jackson||CEO||Buy||3,000||$3.50||$10,500.00|| |
Latest Headlines for Celator Pharmaceuticals (NASDAQ:CPXX)
What is Celator Pharmaceuticals' stock symbol?
Celator Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPXX."
Where is Celator Pharmaceuticals' stock going? Where will Celator Pharmaceuticals' stock price be in 2017?
5 brokers have issued 1-year target prices for Celator Pharmaceuticals' shares. Their forecasts range from $13.00 to $26.00. On average, they anticipate Celator Pharmaceuticals' stock price to reach $21.20 in the next twelve months.
When will Celator Pharmaceuticals announce their earnings?
Celator Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 9th 2016.
How do I buy Celator Pharmaceuticals stock?
Shares of Celator Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Celator Pharmaceuticals stock cost?
One share of Celator Pharmaceuticals stock can currently be purchased for approximately $30.24.
Celator Pharmaceuticals (NASDAQ:CPXX) Chart for Thursday, February, 23, 2017
Institutional Ownership ChartEarnings History ChartDividend History Chart